Tonix Pharmaceuticals Holding Corp (OQ:TNXP)

Apr 01, 2024 04:15 pm ET
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the fourth quarter and...
Mar 28, 2024 09:32 am ET
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered into a securities purchase agreement with existing healthcare focused institutional investors of the Company...
Mar 25, 2024 08:00 am ET
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the U.S. Food and Drug Administration (FDA) has granted Rare...
Mar 21, 2024 08:00 am ET
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announces a poster presentation at the American Chemistry Society (ACS)...
Mar 20, 2024 08:00 am ET
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced it has selected two contract manufacturing organizations (CMOs),...
Mar 19, 2024 08:00 am ET
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will achieve its goal of transitioning to a fully...
Mar 12, 2024 08:00 am ET
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix...
Mar 11, 2024 08:00 am ET
Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Contr
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the presentation of additional efficacy data from RESILIENT, the...
Mar 07, 2024 09:37 am ET
New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT
FMW Media's New to The Street announces the broadcasting of its business show that will air as a sponsored program on Bloomberg TV tonight, Thursday, March 7, 2024, at 9:30 PM PT. New to The Street's TV episode 560 will air the following five...
Mar 07, 2024 08:00 am ET
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the publication of a research paper in the Journal Psychiatry...
Mar 06, 2024 08:00 am ET
Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that EVERSANA®, a leading provider of commercialization services...
Mar 05, 2024 08:00 am ET
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the results of modeling key human pharmacokinetic (PK) properties for TNX-1500...
Feb 29, 2024 08:00 am ET
Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer, will present...
Feb 28, 2024 08:00 am ET
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the completion of the clinical stage of its Phase 1, single ascending dose escalation...
Feb 27, 2024 08:00 am ET
Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya™ to Support Development and Partnering in Japan and China
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced positive results from its clinical pharmacokinetic (PK) bridging study...
Feb 26, 2024 08:00 am ET
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Bedtime drug being developed by Tonix relieved pain by targeting fibromyalgia's characteristic "non-restorative sleep": Potential for FDA Approval in 2025
Feb 23, 2024 09:30 am ET
New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series
FMW Media Work announces that its "New to The Street Leadership," Powered by Sector SPDR ETFs, will air on Bloomberg TV as sponsored programming on Saturday, February 24, 2024, at 6:30 PM ET, and the "New to The Street" business show will air on...
Feb 20, 2024 08:00 am ET
Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer...
Feb 16, 2024 09:30 am ET
New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT
FMW Media Works Corp.'s New to the Street, a nationally broadcasted business television production, announces airing Episode 556 on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT. New to The Street's Episode 556 line-up...
Feb 15, 2024 08:45 am ET
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
FN Media Group News Commentary - Numerous reports indicate that the fibromyalgia treatment market is positioned to continue to grow at a substantial rate through the next decade. Fibromyalgia is a chronic condition whose symptoms severely impair...
Feb 15, 2024 08:00 am ET
Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Risk of Addiction
Non-opioid drug candidate from Tonix lowered pain and also improved sleep and fatigue
Feb 14, 2024 08:00 am ET
Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, held a key opinion leader (KOL) webinar to discuss the positive Phase 3 data of...
Feb 13, 2024 08:00 am ET
Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it has engaged Rho, Inc. (Rho), a global contract research...
Feb 12, 2024 08:00 am ET
Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the U.S. Food and Drug Administration (FDA) has cleared the...
Feb 01, 2024 08:00 am ET
New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval
Fibromyalgia candidate TNX-102 SL hits primary endpoint of daily pain reduction (p=0.00005)Combination of broad-spectrum relief and favorable tolerability seen as distinguishing, competitive featuresCompany plans to file an NDA for FDA approval in 2H 2024
Jan 31, 2024 07:00 am ET
Tonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVID
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates and currently focused on preparing a New Drug Application (NDA) for Tonmya...
Jan 29, 2024 07:00 am ET
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya™ as Trade Name for TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the U.S. Food and Drug Administration (FDA) has...
Jan 25, 2024 07:00 am ET
Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced a key opinion leader (KOL) webinar to discuss the positive Phase...
Jan 09, 2024 07:00 am ET
Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the presentation of additional safety and tolerability data from...
Jan 03, 2024 07:00 am ET
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix...
Dec 20, 2023 10:35 am ET
Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 Million
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company has signed securities purchase agreements with certain...
Dec 20, 2023 10:30 am ET
Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Phase 3 RESILIENT study evaluating TNX-102 SL...
Dec 14, 2023 09:15 am ET
Dec 11, 2023 07:00 am ET
Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public Meeting
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present...
Dec 04, 2023 07:00 am ET
Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug...
Nov 28, 2023 07:00 am ET
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Tonix Management will present and host investor meetings at the following December...
Nov 15, 2023 07:00 am ET
Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the completion of the clinical phase of the Phase 3...
Nov 13, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the first participant was enrolled in an...
Nov 09, 2023 04:15 pm ET
Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the third quarter ended September 30,...
Nov 02, 2023 08:00 am ET
Tonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the...
Oct 31, 2023 05:00 pm ET
Tonix Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced topline results from the Phase 2 proof-of-concept double-blind, randomized,...
Oct 30, 2023 07:00 am ET
Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Co
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced data from two oral presentations which were delivered recently...
Oct 26, 2023 07:00 am ET
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the completion of the clinical phase of the Phase 2 proof-of-concept, double-blind,...
Oct 25, 2023 08:45 am ET
New Hope for Long COVID Sufferers
Tonix's Therapeutic Development Program is Aligned with National Goal for Better Solutions
Oct 19, 2023 07:00 am ET
Tonix Pharmaceuticals Presents Data from its Horsepox-Based Vaccine Development Platform at the World Vaccine Congress Europe
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, presented data on its horsepox-based live virus vaccine platform in an oral presentation at the World...
Oct 18, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Anima
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that a study published in the Journal Nature1 by faculty at the...
Oct 16, 2023 07:00 am ET
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the completion of the clinical phase of the Phase 2 potential registration-quality, double-blind, randomized, multicenter,...
Oct 12, 2023 07:00 am ET
Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at...
Oct 11, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Zeil Rosenberg, M.D., M.P.H., Executive Vice President, Medical, Tonix...
Oct 09, 2023 07:00 am ET
Tonix Pharmaceuticals Provides Overview of TNX-2900 Program for the Treatment of Prader-Willi Syndrome at the Foundation for Prader-Willi Research Family Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, provided an overview of...
Oct 04, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the European Patent Office (EPO) issued European Patent No. 3242676 to the Company on October 4, 2023. The patent, entitled...
Sep 28, 2023 09:00 pm ET
Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale...
Sep 28, 2023 04:01 pm ET
Tonix Pharmaceuticals Announces Proposed Public Offering
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to...
Sep 27, 2023 08:30 am ET
Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reacti
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company, today announced that the University of North Carolina (UNC) Institute for Trauma Recovery has been awarded a $3 million grant from the...
Sep 21, 2023 07:00 am ET
Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced a poster presentation showing research results for mTNX-1700 (murine trefoil factor...
Sep 18, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congress
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that David C. Yeomans, Ph.D. presented data relevant to the...
Sep 15, 2023 09:30 am ET
New to The Street Announces Episodes 510 and 511 Six Corporate Interviews, airings on Newsmax and FOX Business Network, Broadcastings Begin Saturday, September 16, 2023, at 3:30 PM ET
FMW Media's New to The Street announces their corporate interviews for episodes 510 and 511 that will air on Newsmax and the FOX Business Network. New to The Street airs on Newsmax, Episode 510, on Saturday, September 16, 2023, at 3:30 PM...
Sep 14, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced a poster presentation at the Seventh International Cancer Immunotherapy Conference 2023 (CICON23): Translating...
Sep 06, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Commitment to Supply Tosymra® (sumatriptan Nasal Spray) 10 mg for Treatment of Acute Migraine to Meet Potential Increased Demand Following GSK’s Planned Discontinuation
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it is committed to meeting potential increased demand for...
Sep 05, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced topline results from the Phase 2 proof-of-concept PREVAIL study...
Aug 21, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it received the official written response from a Type B...
Aug 17, 2023 07:00 am ET
Tonix Pharmaceuticals to Present at the August Virtual Investor Summit
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will...
Aug 16, 2023 07:00 am ET
Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the initiation of a Phase 1 single ascending dose escalation study of TNX-1500...
Aug 10, 2023 04:30 pm ET
Tonix Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an overview of recent operational highlights. “We...
Aug 07, 2023 07:00 am ET
Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company, today announced the completion of the clinical phase of the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL as a potential treatment for...
Aug 01, 2023 04:01 pm ET
Tonix Pharmaceuticals Announces Closing of $7 Million Public Offering
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced the closing of its public offering of 7,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and...
Aug 01, 2023 07:00 am ET
Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company, today announced that it has completed enrollment of its potentially final, confirmatory Phase 3 RESILIENT trial of TNX-102 SL (cyclobenzaprine...
Jul 31, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the investigator-initiated Phase 2 Study of The Results of Oxytocin in...
Jul 27, 2023 09:31 pm ET
Tonix Pharmaceuticals Announces Pricing of $7 Million Public Offering
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,000,000 shares of its common stock (or...
Jul 27, 2023 04:01 pm ET
Tonix Pharmaceuticals Announces Proposed Public Offering
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to...
Jul 26, 2023 04:05 pm ET
Tonix Pharmaceuticals Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quar
Tianeptine New Findings Support Development of TNX-4300 as a First-in-Class Oral Therapy in Depression, Alzheimer’s Disease and Other Psychiatric and Neurodegenerative Conditions with Memory Deficits CHATHAM, N.J., July 26, 2023 (GLOBE...
Jul 24, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognitio
Tianeptine (Estianeptine) as First-in-Class Oral Therapies in Alzheimer’s Disease and Other Psychiatric and Neurodegenerative Conditions with Memory Deficits (S)-Tianeptine Effects on Novel Object Recognition are Consistent with a Role for PPAR-β/δ...
Jul 17, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorde
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company, today announced that the first participant has been enrolled in a Phase 2 investigator-initiated, proof-of-concept study of TNX-1900 (potentiated intranasal oxytocin)...
Jul 10, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the Phase 2 ‘POWER’ study of TNX-1900 (intranasal potentiated...
Jul 06, 2023 07:00 am ET
Tonix Pharmaceuticals Comments on Two Long COVID Conferences Sponsored by the U.S. National Academies
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company, today announced comments relating to two recent meetings sponsored by the National Academies of Sciences, Engineering, and Medicine (National...
Jul 03, 2023 07:00 am ET
Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix Pharmaceuticals or Tonix), a biopharmaceutical company, and its wholly-owned commercialization subsidiary Tonix Medicines, Inc. (Tonix Medicines), today announced it has completed the...
Jun 26, 2023 07:00 am ET
Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix Pharmaceuticals or Tonix) and its wholly-owned subsidiary Tonix Medicines, Inc. (Tonix Medicines), a clinical-stage biopharmaceutical company, today announced that they have entered into an...
Jun 15, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Publication of Results from Phase 3 RELIEF Trial of TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that previously disclosed results from the Phase 3 RELIEF study of TNX-102 SL for the management of fibromyalgia have been published in...
Jun 07, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2023 Americ
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced data from two oral presentations and one poster presentation at the 2023 American Transplant Congress (ATC) by...
Jun 05, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Presentation of Data Supporting Development of Racemic and Single (S)-Isomer Tianeptine, Plastogen Anti-Depressants, at the American Society of Clinical Psychopharmacol
Isomer of Tianeptine, or TNX-4300, is Free from µ-Opioid Receptor Activity Associated with the (R)-Isomer TNX-4300 is in Preclinical Development for Depression, Bipolar Disorder, Alzheimer’s Disease and Parkinson’s Disease CHATHAM, N.J., June 05,...
May 31, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant Congress
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an upcoming oral presentation by Ryo Otsuka, Ph.D., and poster presentation by Kohei Kinoshita, M.D at the 2023...
May 30, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Presentation at the 2023 BIO International Convention
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the 2023 BIO...
May 25, 2023 04:05 pm ET
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq...
May 25, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present a poster at the 2023 American Society of...
May 24, 2023 07:00 am ET
Tonix Pharmaceuticals to Present at the June 1st Virtual Investor Summit
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the June 1st Virtual Investor Summit on Thursday,...
May 23, 2023 07:00 am ET
Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative Diseases
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the isolation and functional characterization of the two mirror image isomers of racemic tianeptine, which is...
May 22, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin)
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a research collaboration agreement to evaluate the effect of TNX-1900 (intranasal potentiated oxytocin) on...
May 18, 2023 07:00 am ET
Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that management will participate in the A.G.P. Virtual Healthcare Conference and host investor meetings. The conference is being held...
May 17, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the molecular mechanism of action of tianeptine, the active ingredient of TNX-601 ER (tianeptine hemioxalate...
May 09, 2023 01:00 pm ET
Tonix Pharmaceuticals Announces 1-for-6.25 Reverse Stock Split
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will effect a 1-for-6.25 reverse stock split of its outstanding common stock. This will be effective for...
May 08, 2023 07:00 am ET
Tonix Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent operational...
May 04, 2023 07:00 am ET
Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to support a Phase 1 clinical...
Apr 27, 2023 08:00 am ET
A New Depression Drug Being Developed by Tonix May Side-Step Treatment-Limiting Effects of Nearly All Current Antidepressants in the US
No Evidence of Sexual Dysfunction or Weight Gain with its Active Ingredient as a Prescription Drug Outside the U.S.
Apr 19, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Presentations of Pre-Clinical Data on TNX-1700 in Syngeneic Models of Colorectal and Gastric Cancer at the American Association for Cancer Research Annual Meeting 2023
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the presentation of two posters with research results on TNX-1700 (recombinant TFF2 – albumin fusion peptide) at the American...
Apr 17, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft Survival
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the on-line publication of two papers1,2 in the American Journal of Transplantation by faculty at the Center for Transplantation...
Apr 13, 2023 07:00 am ET
Tonix Pharmaceuticals Expedites Fibromyalgia and Chronic Migraine Programs
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it is eliminating the interim analyses in its registration-enabling, confirmatory Phase 3 RESILIENT study of TNX-102 SL for...
Apr 06, 2023 04:15 pm ET
Tonix Pharmaceuticals Presents Data from its Vaccine Development Program at the World Vaccine Congress
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, presented data from its live virus vaccine platform development program in two oral presentations at the World Vaccine Congress...
Apr 05, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Poster Presentations at the American Association for Cancer Research Annual Meeting 2023
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that two posters with research results on TNX-1700 (recombinant TFF2 – albumin fusion peptide) will be presented as posters at the...
Apr 04, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Pipeline Prioritization Update for 2023
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced it is reallocating resources and cash to streamline its pipeline and focus on its mid- and late-stage clinical programs within its core...
Mar 30, 2023 07:00 am ET
Tonix Pharmaceuticals Presents Positive Efficacy and Safety Data from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 5th International Congress on Controversies in Fibrom
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present an oral presentation and...
Mar 27, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Oral Presentations at the World Vaccine Congress
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Zeil Rosenberg, M.D., M.P.H., Executive Vice President, Medical and Farooq Nasar, Ph.D., Senior Principal Investigator, both of...
Mar 23, 2023 04:15 pm ET
Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Pa
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, delivered an oral...
Mar 23, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Oral Presentation and Poster at the 5th International Congress on Controversies in Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver an oral presentation and the Company will...
Mar 22, 2023 07:00 am ET
Tonix Pharmaceuticals to Present at the 2023 Virtual March Investor Summit
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Virtual March Investor Summit on Wednesday,...
Mar 16, 2023 04:05 pm ET
Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, will deliver a presentation...
Mar 16, 2023 07:00 am ET
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the Phase 2 ‘UPLIFT’ study of TNX-601 ER1 (tianeptine hemioxalate...
Mar 13, 2023 07:00 am ET
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an overview of...
Mar 07, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Results from a Preclinical Study of Murine TNX-1700 Presented in a Poster at the Keystone Symposia, “Cancer Immunotherapy: Mechanisms of Response Versus Resistance”
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of mTNX-1700 (recombinant murine TFF2-murine serum albumin, or MSA, fusion protein) were...
Feb 23, 2023 04:15 pm ET
Tonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of R. Newcomb Stillwell to its Board of Directors, to be effective as of March 15, 2023. “We are...
Feb 22, 2023 07:00 am ET
Tonix Pharmaceuticals Describes Emerging Research on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients During Event Titled, “Long COVID: What Will it Take to Accelerate Therapeutic Prog
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that during a virtual event co-hosted by BIO and Solve M.E. titled, “Long COVID: What Will it Take to Accelerate...
Feb 16, 2023 07:00 am ET
Tonix Pharmaceuticals to Participate in Event Titled, “Long COVID: What Will it Take to Accelerate Therapeutic Progress?”
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at a...
Feb 14, 2023 09:30 am ET
Sidoti & Company, LLC Announces Registration Now Open for March Small-Cap and May Micro-Cap Conferences
NEW YORK, NY / ACCESSWIRE / February 14, 2023 / Sidoti & Company, LLC announces that its two spring conferences are now open for registration. The March Virtual Small-Cap Conference will take place on Wednesday and Thursday, March 22-23, 2023, and the May Virtual Micro-Cap Conference will be on Wednesday and Thursday, May 10-11, 2023.Sidoti hosts eight virtual investor conferences a year, alternating between small- and micro-cap targeted companies. Companies can host both group pr
Feb 13, 2023 09:30 am ET
New to The Street Announces its Line-up, Four Interviews on Episode #438, Airing on the Fox Business Network, Tonight, Monday, February 13, 2023, 10:30 PM PT
FMW Media’s New to The Street announces the broadcastings of its nationally syndicated shows on the Fox Business Network tonight, Monday, February 13, 2023, at 10:30 PM PT. New to The Street’s 438th TV show features the following four (4)...
Feb 13, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has exercised an option to obtain an exclusive license from Columbia University for the development of a portfolio of fully...
Feb 10, 2023 09:30 am ET
New to The Street / Newsmax TV Announces its Four Corporate Interviews on Episode #437, Broadcast, Saturday, February 11, 2023, 3:30 PM ET
FMW Media's New to The Street / Newsmax TV announces the broadcasting line-up of its nationally syndicated show Saturday, February 11, 2023, at 3:30 PM ET. New to The Street's 437th TV show line-up features the following four (4) corporate...
Feb 09, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Company’s Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801)
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of a paper entitled, “Single Dose of Recombinant Chimeric Horsepox Virus (TNX‐801) Vaccination...
Feb 06, 2023 07:00 am ET
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘PREVENTION’ Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic Migraineurs
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the Phase 2 ‘PREVENTION’ study of TNX-1900 (intranasal potentiated...
Feb 03, 2023 07:00 am ET
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate...
Feb 02, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has acquired all of the assets of Healion Bio, Inc. (Healion) including its entire...
Feb 01, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Research Agreement with University of Maryland, Baltimore, to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Heart Xenograft Transplanta
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has entered into a sponsored research agreement with the University of Maryland, Baltimore (UMB), for the...
Jan 31, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Presentation of Clinical and Non-Clinical TNX-1900 Data at the Annual Headache Cooperative of the Pacific (HCOP) Winter Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that David C. Yeomans, Ph.D., presented data from clinical and nonclinical studies in an oral presentation at the...
Jan 30, 2023 07:00 am ET
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq...
Jan 26, 2023 04:15 pm ET
Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 2nd Wnt & β-catenin Targeted Drug Development Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Tom Hobman, Ph.D., Professor of Cell Biology, University of Alberta, presented data from his laboratory at...
Jan 24, 2023 07:00 am ET
Tonix Pharmaceuticals Announces Publication of Paper in Antiviral Research Highlighting the Company’s Development of Monoclonal Antibody Therapeutics for Monkeypox and Smallpox
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of a paper entitled, “Development of a rapid image-based high-content imaging screening assay to...
Jan 11, 2023 09:56 am ET
Thinking about buying stock in Jaguar Health, Avaya, Marathon Digital, Lucid, or Tonix Pharmaceuticals?
NEW YORK, Jan. 11, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, AVYA, MARA, LCID, and TNXP.
Jan 04, 2023 07:00 am ET
Tonix Pharmaceuticals Appoints Zeil Rosenberg, M.D., M.P.H., as Executive Vice President, Medical for Infectious Disease Programs
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Zeil Rosenberg, M.D., M.P.H. as its new Executive Vice President, Medical. In this role, Dr....
Jan 03, 2023 07:00 am ET
Tonix Pharmaceuticals to Present at Biotech Showcase 2023
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at Biotech Showcase 2023 being held January...
Dec 19, 2022 07:00 am ET
Tonix Pharmaceuticals Achieves Enrollment of First 50 Percent of Participants in the RESILIENT Study, a Potentially Pivotal Confirmatory Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first 50% of participants have been randomized in the Phase 3 RESILIENT study of TNX-102 SL...
Dec 12, 2022 07:34 am ET
Thinking about buying stock in HTG Molecular Diagnostics, Harpoon Therapeutics, Acer Therapeutics, Aptevo Therapeutics, or Tonix Pharmaceuticals?
NEW YORK, Dec. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTGM, HARP, ACER, APVO, and TNXP.
Dec 12, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Curia Global, Inc.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has obtained an exclusive license from Curia Global, Inc., a leading contract research, development and manufacturing...
Dec 05, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoie
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has entered into a sponsored research agreement with Boston Children's Hospital to study TNX-15001...
Dec 01, 2022 07:00 am ET
Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, presented data from the Company’s TNX-801 (live horsepox...
Nov 30, 2022 07:00 am ET
Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced data from its fully human anti-SARS-CoV-2 monoclonal antibody platform in an oral presentation delivered by Seth Lederman, M.D., Chief...
Nov 23, 2022 07:00 am ET
Tonix Pharmaceuticals to Participate in the A.G.P. Biotech Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that management will participate virtually in the A.G.P. Biotech Conference and host investor meetings. The conference is being held...
Nov 22, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine and Immunotherapy Congress
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver an oral presentation at the World Vaccine and...
Nov 21, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Oral Presentation at the World Antiviral Congress
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver an oral presentation at the World Antiviral...
Nov 16, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Data from an in vitro Study of the Impact of Oxytocin on Human Neurons at Neuroscience 2022, the Annual Meeting of the Society for Neuroscience
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced data describing the impact of oxytocin on isolated human sensory neurons, presented at Neuroscience 2022, the annual meeting of the...
Nov 09, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Poster Presentation at Neuroscience 2022 by the Society for Neuroscience
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced a poster presentation by an academic collaborator at Neuroscience 2022 by the Society for Neuroscience being held November 12-16, 2022,...
Nov 07, 2022 07:00 am ET
Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022, and provided an overview of recent operational...
Oct 31, 2022 07:00 am ET
Tonix Pharmaceuticals to Present at the 2022 BioFuture Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at BioFuture on Tuesday, November 8, 2022, at 11:00...
Oct 25, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Pricing of $15 Million Private Placement of Convertible Redeemable Preferred Stock
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 1,400,000 shares of Series A...
Oct 19, 2022 07:00 am ET
Tonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, October...
Oct 17, 2022 09:30 am ET
New to The Street Announces Five Corporate Interviews On Its 397th TV Show Airing On The Fox Business Network, Tonight, Monday, October 17, 2022, at 10:30 PM PT
FMW Media’s New to The Street , a nationally syndicated TV show, announces episode #397 airing on the Fox Business Network, tonight, Monday, October 17, 2022, at 10:30 PM PT. 1). The Sustainable Green Team’s (OTC: SGTM) ($SGTM) interviews with...
Oct 17, 2022 07:00 am ET
Tonix Pharmaceuticals to Participate in the 2022 BIO-Europe Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will participate in one-on-one meetings at the 2022...
Oct 14, 2022 09:30 am ET
New to The Street / Newsmax Announces Episode #396, Nine Corporate Interviews Airing Sunday, October 16, 2022, 10-11 AM ET
FMW Media’s New To The Street / Newsmax announces its 396th show lineup, which features the following nine (9) Corporate interviews, airing Sunday, October 16, 2022, 10-11 AM ET: 1). The Sustainable Team’s (OTC: SGTM) ($SGTM) interviews with Tony...
Oct 13, 2022 07:18 pm ET
New to The Street Announces its Five Business Guest Interviews on Episode #395, Airing on Bloomberg TV as a Sponsored Program, Tonight, October 13, 2022 at 9:30 PM PT
FMW Media’s New to The Street announces the broadcasting of its business show broadcasting as a sponsored program on Bloomberg TV, October 13, 2022, at 9:30 PM PT. New to The Street’s TV show will air the following five (5) business interviews:...
Oct 03, 2022 07:00 am ET
Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to...
Sep 23, 2022 10:30 am ET
New to The Street TV / Newsmax TV Announces Its Corporate Interviews on Episode #389, Airing Sunday, September 25, 2022, 10-11 AM ET
FMW Media’s New To The Street / Newsmax TV announces its Corporate interviews on the 389th show, airing Sunday, September 25, 2022, 10-11 AM ET: 1). PetVivo Holdings, Inc.’s (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) interview with John Lai, CEO &...
Sep 22, 2022 07:00 am ET
Tonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients at IASP 2022 World Congress on Pain
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced data from a retrospective observational database study in patients diagnosed with Long COVID at the International...
Sep 15, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the In
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced data from three oral presentations by faculty at the Center for Transplantation Sciences, Massachusetts General...
Sep 06, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the International Congress of The Transplantation Society (TTS 2022)
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced three oral presentations by academic collaborators at the 29th International Congress of The Transplantation...
Aug 22, 2022 09:30 am ET
New to The Street TV Announces Episodes #378, Five Corporate Interviews, Airing on The Fox Business Network, Tonight, Monday, August 22, 2022, at 10:30 PM PT
FMW Media's New to The Street TV, a nationally syndicated TV show, announces episode #378, airing on the Fox Business Network tonight, Monday, August 22, 2022, at 10:30 PM PT New to The Street’s 378th TV episode features the following five (5)...
Aug 22, 2022 07:00 am ET
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the Phase 2 PREVAIL study of TNX-102 SL1 as a potential treatment for...
Aug 19, 2022 10:00 am ET
New to The Street TV Announces its Five Business Guest Interviews, Episode #376 Airs on Bloomberg TV, Saturday, August 20, 2022, at 6:30 PM ET as Sponsored Programming
FMW Media’s New to The Street TV announces broadcasting its sponsored program business show, airing on Bloomberg TV, Saturday, August 20, 2022, at 6:30 PM ET. New to The Street’s TV episode #376 will air the following five (5) business...
Aug 19, 2022 09:35 am ET
New to The Street TV / Newsmax TV Announces Its Seven Corporate Interviews for This Week’s TV Broadcast, Episode #377, August 21, 2022, 10-11 AM ET
FMW Media’s New To The Street / Newsmax TV announces its 377th show line-up, which features the following seven (7) Corporate interviews, airing Sunday, August 21, 2022, 10-11 AM ET: 1). Tonix Pharmaceuticals, Inc.’s (NASDAQ: TNXP) ($TNXP)...
Aug 15, 2022 09:30 am ET
FMW Media, Inc.’s New to The Street TV Announces its Five Corporate Interviews Airing On Fox Business Network, Monday, August 15, 2022, 10:30 PM PT
FMW Media’s New to The Street TV announces the broadcasting of its national syndicated show on the Fox Business Network, Monday, August 15, 2022, at 10:30 PM PT. New To The Street TV’s 375th show features the following five (5) Companies and...
Aug 12, 2022 09:30 am ET
New to The Street / Newsmax TV Announces Eight Interviews for This Week's 374th TV Broadcast, Sunday, August 14, 2022, Hour Slot 10-11 AM ET
FMW Media's New To The Street / Newsmax TV announces the broadcasting line-up of its national syndicated 1- hour TV show this Sunday, August 14, 2022, airing time 10-11 AM ET. New to The Street TV's 374th show line-up, features the following...
Aug 09, 2022 07:00 am ET
Tonix Pharmaceuticals to Present at the 2022 Virtual Q3 Investor Summit
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the Virtual Q3 Investor Summit on Tuesday,...
Aug 08, 2022 07:00 am ET
Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2022, and provided an overview of recent operational...
Aug 02, 2022 07:00 am ET
Tonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine Intoxication
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has received a Cooperative Agreement grant from the National Institute on Drug Abuse (NIDA), part of the...
Aug 01, 2022 08:30 am ET
Thinking about buying stock in Geovax Labs, Aethlon Medical, Tonix Pharmaceuticals, Inflarx NV, or Redbox Entertainment?
NEW YORK, Aug. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOVX, AEMD, TNXP, IFRX, and RDBX.
Aug 01, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent 11,389,473 to the Company on July 19, 2022. The patent,...
Jul 29, 2022 10:45 am ET
Thinking about buying stock in Intel Corp, Thermogenesis, SIGA Technologies, Tonix Pharmaceuticals, or Sunrun?
NEW YORK, July 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INTC, THMO, SIGA, TNXP, and RUN.
Jul 28, 2022 10:50 am ET
Thinking about buying stock in Athersys, Missfresh, Carnival Corp, Tilray, or Tonix Pharmaceuticals?
NEW YORK, July 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATHX, MF, CCL, TLRY, and TNXP.
Jul 28, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced a collaboration with the Kenya Medical Research Institute (KEMRI) to plan, seek regulatory approval for and...
Jul 27, 2022 10:40 am ET
Thinking about buying stock in Dave, Cidara Therapeutics, Cassava Sciences, Tonix Pharmaceuticals, or Kraft Heinz?
NEW YORK, July 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAVE, CDTX, SAVA, TNXP, and KHC.
Jul 26, 2022 10:40 am ET
Thinking about buying stock in Ayala Pharmaceuticals, Revelation Biosciences, Tonix Pharmaceuticals, Waitr Holdings, or Sundial Growers?
NEW YORK, July 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AYLA, REVB, TNXP, WTRH, and SNDL.
Jul 25, 2022 09:31 am ET
Thinking about buying stock in Aethlon Medical, Tonix Pharmaceuticals, REE Automotive, Kaival Brands, or vTv Therapeutics?
NEW YORK, July 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AEMD, TNXP, REE, KAVL, and VTVT.
Jul 25, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Sina Bavari, Ph.D. as its new Executive Vice President, Infectious Disease Research and...
Jul 11, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced development of TNX-601 ER (tianeptine oxalate extended-release tablets), a naloxone-free formulation of TNX-601...
Jul 06, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Presentation at the World Orphan Drug Congress USA
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will present at the World Orphan Drug Congress USA 2022 being held July 11-13, 2022 at the Hynes Center in...
Jun 27, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Trial Design of New Phase 2 Clinical Study of TNX-1300 for Cocaine Intoxication
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the design of a new Phase 2 clinical trial of TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v....
Jun 24, 2022 09:30 am ET
New to The Street TV / Newsmax TV Announces its Six Interviews for This Week's TV Broadcast, Episode #358, June 26, 2022, 10-11 AM ET
FMW Media's New To The Street / Newsmax TV show announces the broadcasting line-up of its national syndicated 1-hour TV show this Sunday, June 26, 2022, airing time 10-11 AM ET. New to The Street’s 358th TV show line-up, features six (6)...
Jun 22, 2022 09:30 am ET
New to The Street TV Announces Four Business Interviews Airing on the Fox Business Network, Tonight, Wednesday, June 22, 2022, at 11:00 PM PT
FMW Media's New to The Street TV announces the 357th episode broadcasting of its nationally syndicated shows tonight, Wednesday, June 22, 2022, at 11:00 PM PT on Fox Business Network. New to The Street airs tonight its business interviews with the...
Jun 22, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred Stock
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 2,500,000 shares of Series A...
Jun 21, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Publication of Paper in Pharmaceutics on the Enhancing Effect That Magnesium Contributes to in vivo Intranasal Oxytocin Analgesia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced the publication of a paper, entitled "Impact of Magnesium on Oxytocin Receptor Function," in the journal Pharmaceutics, that described results...
Jun 20, 2022 09:30 am ET
New to The Street TV Announces Four Corporate Interviews on its 356th Show Airing on the Fox Business Network, Tonight, Monday, June 20, 2022, at 10:30 PM PT
FMW Media’s New to The Street TV, a nationally syndicated TV show, announces episode #356 airing tonight, Monday, June 20, 2022, at 10:30 PM PT on the Fox Business Network. New to The Street’s 356th TV episode airs tonight, featuring the following...
Jun 16, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Programs in Massachusetts
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a ribbon-cutting ceremony at the Company’s 45,000 square foot clinical-scale manufacturing facility...
Jun 09, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced data from three oral presentations at the 2022 American Transplant Congress (ATC) by faculty at the Center for...
Jun 08, 2022 04:05 pm ET
Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for Virology
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Tom Hobman, Ph.D., Professor, Department of Cell Biology, University of Alberta, presented data from his...
Jun 08, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4th Symposium of the Canadian Society for Virology
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Ryan Noyce, Ph.D., and David Evans, Professor, Department of Cell Biology, University of Alberta, together...
Jun 06, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Presentation at the 2022 BIO International Convention
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the...
Jun 02, 2022 10:26 am ET
BioMed Stocks On the Move: PDSB, NMLSF, TNXP, AIMLF; Leaders Report Latest Advances in Antiviral Vaccines, Novel Therapeutics for Oncology, and Autism and HealthTech Wearables
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Tonix Pharmaceuticals (NASDAQ: TNXP), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), PDS...
Jun 02, 2022 09:31 am ET
Thinking about buying stock in 180 Life Sciences, Obsidian Energy, Tonix Pharmaceuticals, Nio, or SoFi Technologies?
NEW YORK, June 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATNF, OBE, TNXP, NIO, and SOFI.
Jun 02, 2022 07:00 am ET
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. On June 1,...
Jun 01, 2022 08:30 am ET
Thinking about buying stock in Tonix Pharmaceuticals, View, vTv Therapeutics, TherapeuticsMD, or Cassava Sciences?
NEW YORK, June 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNXP, VIEW, VTVT, TXMD, and SAVA.
Jun 01, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-801 Smallpox and Monkeypox Vaccine and Recombinant Pox Virus (RPV) Platform Technology
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,345,896 to the Company on May 31, 2022. This...
May 31, 2022 04:05 pm ET
Tonix Pharmaceuticals Announces Share Repurchase Program
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a share repurchase program pursuant to which the Company may repurchase...
May 31, 2022 07:00 am ET
Tonix Pharmaceuticals Announces Two Oral Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) on Prevention of Rejection in Kidney and Heart Allograft Transplantation at the 2022 American Tra
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced two upcoming oral presentations by faculty at the Center for Transplantation Sciences, Massachusetts General...
May 27, 2022 09:30 am ET
New to The Street TV / Newsmax TV announces its 348th Episode with Seven Interviews on This Week’s TV Broadcast, Airing May 29, 2022, 10-11 AM ET
FMW Media’s New to The Street / Newsmax TV announces the broadcasting line-up of its national syndicated 1- hour TV show this Sunday, May 29, 2022, airing time 10-11 AM ET. New to The Street’s 348th TV episode line-up features seven (7) interviews...
May 23, 2022 10:59 am ET
Thinking about buying stock in DiDi Global, Farmmi, Tonix Pharmaceuticals, Redbox, or Rivian Automotive?
NEW YORK, May 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIDI, FAMI, TNXP, RDBX, and RIVN.
May 19, 2022 08:30 am ET
Thinking about buying stock in Indaptus Therapeutics, Canaan, Tonix Pharmaceuticals, Xos, or Mersana Therapeutics?
NEW YORK, May 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INDP, CAN, TNXP, XOS, and MRSN.
May 18, 2022 07:00 am ET
Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a license agreement and extended a research collaboration with the University of Alberta, a...
May 17, 2022 09:31 am ET
Thinking about buying stock in Bird, On, Sundial Growers, Tonix Pharmaceuticals, or Paramount?
NEW YORK, May 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BRDS, ONON, SNDL, TNXP, and PARA.
May 16, 2022 01:00 pm ET
Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock. This will be effective for...
May 16, 2022 09:30 am ET
New to The Street TV announces its 345th Episode, Airing Four Corporate Interviews, on the Fox Business Network, Tonight, Monday, May 16, 2022, at 10:30 PM PT
FMW Media's New to The Street TV, a nationally syndicated TV show, announces episode #345, airing tonight, May 16, 2022, on the Fox Business Network. New to The Street’s 345th episode airs tonight, Monday, May 16, 2022, on the Fox Business...
May 13, 2022 09:30 am ET
New to The Street T.V. / Newsmax T.V. Announces its Eight Corporate Interviews Airing Sunday, May 15, 10-11 AM ET
FMW Media's New to The Street / Newsmax T.V. announces on Sunday, May 15, 2022, the broadcasting line-up of its national syndicated 1-hour T.V. show, airing 10-11 AM ET. New to The Street's 344th T.V. episode line-up, features eight (8) interviews...
May 09, 2022 07:00 am ET
Tonix Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022, and provided an overview of recent operational...
May 06, 2022 09:31 am ET
Thinking about buying stock in TPI Composites, Sema4 Holdings, Highpeak Energy, Intercept Pharmaceuticals, or Tonix Pharmaceuticals?
NEW YORK, May 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TPIC, SMFR, HPK, ICPT, and TNXP.
Apr 28, 2022 07:00 am ET
Tonix Pharmaceuticals to Present at the 2022 Q2 Investor Summit
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the 2022 Q2 Investor Summit on Wednesday, May 4,...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.